Theranostic Nanovesicles for Ocular Angiogenesis Therapy

目前的治疗湿性年龄相关性黄斑变性（AMD）的标准是玻璃体内注射 血管内皮生长因子（VEGF）抑制剂已经改变了治疗模式。但不少 患有脉络膜新生血管（CNV）的AMD患者对抗VEGF治疗无效或患有 与反复玻璃体内注射相关的并发症。因此，非常需要 开发替代治疗模式，包括新的治疗剂和递送方法， 治疗AMD患者的CNV。 某些整合素在脉络膜和视网膜新生血管上的选择性表达使整合素成为视网膜新生血管的一部分。 理想靶点，而递送整联蛋白拮抗剂可以使用干细胞衍生的纳米囊泡进行工程化 该系统是生物相容的并且适合于穿过眼部屏障。我们假设， 干细胞衍生的超顺磁性氧化铁颗粒（SPIO）标记的外泌体， 拮抗剂将提供有效抑制或消退CNV的有效治疗诊断剂，具有直接抑制或逆转CNV的能力。 可视化和定量评估药物在体内的分布。在具体目标1中，我们将全面发展和 表征纳米囊泡制剂并测试它们的细胞毒性、抗血管生成特性以及 磁粒子成像（MPI）灵敏度。在具体目标2中，我们将测试工程设计的假设， 纳米囊泡系统提高了CNV在体内的治疗效果，并使纵向MPI成像成为可能。 药物分布的量化。在这个目标中，我们将确定SPIO标记的药物缀合物 在激光诱导的CNV上的纳米囊泡，并通过非侵入性MPI成像分析药物分布的动力学。 拟议的研究带来了眼科，药物输送，MPI 成像和视网膜疾病的动物模型，以解决有效药物递送到视网膜的关键挑战。 眼睛的后段。成功完成拟议的活动将产生广泛的影响 用于推进干细胞衍生的纳米囊泡作为治疗眼的新型治疗诊断剂的开发， 血管疾病和其他血管生成相关疾病。

The current standard of care for wet age-related macular degeneration (AMD) with intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors has transformed the treatment paradigm. However, many AMD patients with choroidal neovascularization (CNV) either fail to respond to anti-VEGF therapy or suffer from complications associated with repeated intravitreal injections. Therefore, there is great need for developing alternative treatment modalities, including novel therapeutic agents and delivery methods, to combat CNV for patients with AMD. The selective expression of certain integrins on choroidal and retinal neovasculature makes integrin an ideal target, while delivery of integrin antagonists can be engineered using stem cell-derived nanovesicle system that is biocompatible and amenable for crossing the ocular barriers. We hypothesize that modification of the stem cell-derived, superparamagnetic iron oxide particle (SPIO)-labeled exosomes to deliver an integrin antagonist will provide a potent theranostic agent to effectively inhibit or regress CNV with the ability to directly visualize and quantitatively assess drug distribution in vivo. In Specific Aim 1, we will develop and fully characterize the nanovesicle formulations and test their cytotoxicity, antiangiogenic property, as well as magnetic particle imaging (MPI) sensitivity. In Specific Aim 2, we will test the hypothesis that the engineered nanovesicle system improves the therapeutic efficacy of CNV in vivo and enables MPI imaging for longitudinal quantification of drug distribution. In this aim, we will determine the effect of SPIO-labeled, drug-conjugated nanovesicles on Iaser-induced CNV and analyze the kinetics of drug distribution by noninvasive MPI imaging. The proposed study brings a unique combination of expertise in ophthalmology, drug delivery, MPI imaging, and animal model of retinal diseases, to address the critical challenges for efficient drug delivery into the posterior segment of the eye. Successful completion of the proposed activities will have vast ramifications for advancing the development of stem cell-derived nanovesicles as novel theranostic agent for treating ocular vascular diseases and other angiogenesis-related disorders.